Skip to main content
Bulletin of the World Health Organization logoLink to Bulletin of the World Health Organization
. 1998;76(4):353–359.

Comparison of AIK-C measles vaccine in infants at 6 months with Schwarz vaccine at 9 months: a randomized controlled trial in Ghana.

F K Nkrumah 1, M Osei-Kwasi 1, S K Dunyo 1, K A Koram 1, E A Afari 1
PMCID: PMC2305762  PMID: 9803586

Abstract

In a randomized controlled trial in a measles endemic area, standard-dose (4.0 log10pfu) AIK-C measles vaccine administered at 6 months of age was compared to standard-dose Schwarz vaccine (3.7log10pfu) given at 9 months. Seroconversion rates at 3 and 6 months after immunization in the two groups were comparable and similar. The geometric mean titres achieved were, however, significantly higher in the Schwarz group (P < 0.05). No immediate serious side-effects were observed with either vaccine. We conclude that standard-dose AIK-C measles vaccine can be recommended for measles immunization in children below 9 months of age, especially in highly endemic and high-risk areas in developing countries.

Full text

PDF
353

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aaby P., Bukh J., Lisse I. M., da Silva M. C. Further community studies on the role of overcrowding and intensive exposure on measles mortality. Rev Infect Dis. 1988 Mar-Apr;10(2):474–477. doi: 10.1093/clinids/10.2.474. [DOI] [PubMed] [Google Scholar]
  2. Albrecht P., Ennis F. A., Saltzman E. J., Krugman S. Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure. J Pediatr. 1977 Nov;91(5):715–718. doi: 10.1016/s0022-3476(77)81021-4. [DOI] [PubMed] [Google Scholar]
  3. Black F. L., Berman L. L., Libel M., Reichelt C. A., Pinheiro F. D., Travassos da Rosa A., Figueira F., Siqueira Gonzales E. Inadequate immunity to measles in children vaccinated at an early age: effect of revaccination. Bull World Health Organ. 1984;62(2):315–319. [PMC free article] [PubMed] [Google Scholar]
  4. Bolotovski V. M., Grabowsky M., Clements C. J., Albrecht P., Brenner E. R., Zargaryantzs A. I., Litvinov S. K., Mikheyeva I. V. Immunization of 6 and 9 month old infants with AIK-C, Edmonston-Zagreb, Leningrad-16 and Schwarz strains of measles vaccine. Int J Epidemiol. 1994 Oct;23(5):1069–1077. doi: 10.1093/ije/23.5.1069. [DOI] [PubMed] [Google Scholar]
  5. Burström B., Aaby P., Mutie D. M. Measles in infants: a review of studies on incidence, vaccine efficacy and mortality in east Africa. East Afr Med J. 1995 Mar;72(3):155–161. [PubMed] [Google Scholar]
  6. Dabis F., Sow A., Waldman R. J., Bikakouri P., Senga J., Madzou G., Jones T. S. The epidemiology of measles in a partially vaccinated population in an African city: implications for immunization programs. Am J Epidemiol. 1988 Jan;127(1):171–178. doi: 10.1093/oxfordjournals.aje.a114778. [DOI] [PubMed] [Google Scholar]
  7. Hull H. F., Williams P. J., Oldfield F. Measles mortality and vaccine efficacy in rural West Africa. Lancet. 1983 Apr 30;1(8331):972–975. doi: 10.1016/s0140-6736(83)92091-3. [DOI] [PubMed] [Google Scholar]
  8. Loening W. E., Coovadia H. M. Age-specific occurrence rates of measles in urban, peri-urban, and rural environments: implications for time of vaccination. Lancet. 1983 Aug 6;2(8345):324–326. doi: 10.1016/s0140-6736(83)90299-4. [DOI] [PubMed] [Google Scholar]
  9. Makino S. Development and characteristics of live AIK-C measles virus vaccine: a brief report. Rev Infect Dis. 1983 May-Jun;5(3):504–505. doi: 10.1093/clinids/5.3.504. [DOI] [PubMed] [Google Scholar]
  10. Malfait P., Jataou I. M., Jollet M. C., Margot A., De Benoist A. C., Moren A. Measles epidemic in the urban community of Niamey: transmission patterns, vaccine efficacy and immunization strategies, Niger, 1990 to 1991. Pediatr Infect Dis J. 1994 Jan;13(1):38–45. doi: 10.1097/00006454-199401000-00009. [DOI] [PubMed] [Google Scholar]
  11. Sabin A. B., Flores Arechiga A., Fernández de Castro J., Sever J. L., Madden D. L., Shekarchi I., Albrecht P. Successful immunization of children with and without maternal antibody by aerosolized measles vaccine. I. Different results with undiluted human diploid cell and chick embryo fibroblast vaccines. JAMA. 1983 May 20;249(19):2651–2662. [PubMed] [Google Scholar]
  12. Taylor W. R., Mambu R. K., ma-Disu M., Weinman J. M. Measles control efforts in urban Africa complicated by high incidence of measles in the first year of life. Am J Epidemiol. 1988 Apr;127(4):788–794. doi: 10.1093/oxfordjournals.aje.a114860. [DOI] [PubMed] [Google Scholar]
  13. Tidjani O., Grunitsky B., Guérin N., Lévy-Bruhl D., Lecam N., Xuereff C., Tatagan K. Serological effects of Edmonston-Zagreb, Schwarz, and AIK-C measles vaccine strains given at ages 4-5 or 8-10 months. Lancet. 1989 Dec 9;2(8676):1357–1360. doi: 10.1016/s0140-6736(89)91967-3. [DOI] [PubMed] [Google Scholar]
  14. Ueda S., Takahashi M., Minekawa Y., Ogino T., Suzuki N. Studies on further attenuated live measles vaccine. II. Correlation between the titer of the vaccine, the antibody response and clinical reactions. Biken J. 1970 Jun;13(2):117–120. [PubMed] [Google Scholar]
  15. Whittle H. C., Rowland M. G., Mann G. F., Lamb W. H., Lewis R. A. Immunisation of 4-6 month old Gambian infants with Edmonston-Zagreb measles vaccine. Lancet. 1984 Oct 13;2(8407):834–837. doi: 10.1016/s0140-6736(84)90873-0. [DOI] [PubMed] [Google Scholar]

Articles from Bulletin of the World Health Organization are provided here courtesy of World Health Organization

RESOURCES